Nabriva Therapeutics plc

📍 Dublin, Ireland🗓 Founded 2006👥 55 employees💰 Last funded Jun 2021
Biotechnology Research🌐 nabriva.com
Website LinkedIn
Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of novel antibiotics to treat serious infections. Nabriva Therapeutics has two products: Xenleta (lefamulin), recently approved by the FDA for both Oral and IV use and CONTEPO (fosfomycin) for injection, we submitted an NDA for CONTEPO, a potential first-in-class epoxide antibiotic in the United States for complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP). Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA. Nabriva is a commercial-stage biopharmaceutical company with locations in the United States (King of Prussia, PA, San Diego, CA), Austria (Vienna), and Ireland (Dublin), home of our corporate headquarters.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2006
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Nabriva Therapeutics plc?
Nabriva Therapeutics plc has 1 investors on record on gritt.io.
When did Nabriva Therapeutics plc last raise funding?
The most recent investment in Nabriva Therapeutics plc recorded on gritt.io was in June 2021.
When was Nabriva Therapeutics plc founded?
Nabriva Therapeutics plc was founded in 2006.
What industry is Nabriva Therapeutics plc in?
Nabriva Therapeutics plc operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Nabriva Therapeutics plc based?
Nabriva Therapeutics plc is headquartered in Dublin, Ireland.